Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 6Terminated 4Withdrawn 3Unknown 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 20Breast 9Thoracic 6Sarcoma 5Head & Neck 5Dermatologic 5Gynecologic 4Genitourinary 4Other solid neoplasm 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Ovarian Neoplasms 3Uterine Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Adenocarcinoma, Clear Cell 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Celecoxib × Gynecologic × Clear all
NCT02432378 2025-06-19

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Roswell Park Cancer Institute

Phase 1/2 Terminated
25 enrolled
Gynecologic

Ovarian Neoplasms

NCT01175772 2015-06-23

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

HaEmek Medical Center, Israel

Phase 2 Terminated
6 enrolled
Gynecologic

Carcinoma, Ovarian Neoplasms

NCT00084448 2013-07-09

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Terminated
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00231829 2012-04-24

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Montefiore Medical Center

Phase 2 Terminated
23 enrolled
Gynecologic

Uterine Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡